Lexology July 29, 2024
Barnes & Thornburg LLP

Highlights

The HHS-OIG released a favorable opinion regarding refunds and discounts offered to a treatment center for a drug manufactured by the corporation offering the assistance

The discounts offered under the proposed arrangement satisfy the “discount” safe harbor to the Anti-Kickback Statute (AKS)

The proposed arrangement included factors, the agency said, that limited risk under the AKS and the civil monetary penalty laws (CMP)

The U.S. Department of Health and Human Services’ Office of Inspector General (HHS-OIG) recently released OIG Advisory Opinion 24-04, a favorable opinion regarding the federal Anti-Kickback Statute (AKS) and civil monetary penalty laws (CMP) against beneficiary inducements as applied to a refund program and discount program. The program was offered by an affiliate of a drug...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Govt Agencies, OIG, Pharma, Pharma / Biotech
HHS-OIG Highlights Anti-Fraud Safeguards of Drug Manufacturer’s Free Drug Program for Patients in Financial Need
Putting infection control to the test
HHS OIG Finds Favorably for Free Access to Pharmaceutical Product
FDA’s Recent Guidance on Accelerated Approval and Implications for Rare Diseases
Medicare Part D Spending on 10 Diabetes Drugs Hit $35.8B in 2023

Share This Article